Our latest news
What We’re Working On
Media Contact
Dan Budwick
dan@1abmedia.com
Bringing Meaningful Therapies from One to Many
-
March 3rd, 2025
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-0871, a Novel TRPV4 Inhibitor, for the Treatment of Charcot Marie Tooth Disease 2C
Read More -
February 25th, 2025
Actio Biosciences to Participate in Upcoming Investor Conferences
Read More -
January 8th, 2025
Actio Biosciences Expands Leadership Team with Appointment of Cayce Denton as Chief Financial Officer
Read More -
January 6th, 2025
Actio Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read More -
November 12th, 2024
Actio Biosciences to Participate in Upcoming Investor Conferences
Read More